Last reviewed 2026-04-22 · How we verify

Corticosteroids + Rivaroxaban

This combination uses corticosteroids to suppress inflammation and immune responses while rivaroxaban prevents blood clots by inhibiting Factor Xa in the coagulation cascade.

This combination uses corticosteroids to suppress inflammation and immune responses while rivaroxaban prevents blood clots by inhibiting Factor Xa in the coagulation cascade. Used for Phase 3 investigational combination therapy (specific indication not publicly disclosed).

At a glance

Mechanism of action

Corticosteroids work by binding glucocorticoid receptors to reduce inflammatory cytokine production and immune cell activation. Rivaroxaban is a direct Factor Xa inhibitor that blocks the intrinsic and extrinsic coagulation pathways. Together, this combination addresses both inflammatory and thrombotic components of disease, likely in a condition where both pathways contribute to pathology.

Approved indications

• Phase 3 investigational combination therapy (specific indication not publicly disclosed)

Common side effects

• Bleeding (rivaroxaban-related)
• Infection risk (corticosteroid-related)
• Hyperglycemia (corticosteroid-related)
• Osteoporosis (corticosteroid-related)

Key clinical trials

• Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.